2015
DOI: 10.1016/j.tips.2015.02.008
|View full text |Cite
|
Sign up to set email alerts
|

Endocannabinoid signaling at the periphery: 50 years after THC

Abstract: Fifty years ago (in 1964) the psychoactive ingredient of Cannabis sativa, Δ9-tetrahydrocannabinol (THC), was isolated. Nearly 30 years later the endogenous counterparts of THC, collectively termed endocannabinoids (eCBs), were discovered: N-arachidonoylethanolamine (anandamide, AEA) in 1992, and 2-arachidonoylglycerol (2-AG) in 1995. Since then, considerable research has shed light on the impact of eCBs on human health and disease, identifying an ensemble of proteins that bind, synthesize and degrade them, and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

7
580
0
13

Year Published

2015
2015
2024
2024

Publication Types

Select...
4
4

Relationship

2
6

Authors

Journals

citations
Cited by 571 publications
(600 citation statements)
references
References 180 publications
(190 reference statements)
7
580
0
13
Order By: Relevance
“…1F). These results confirm previous data documenting the presence of FAAH in cellular components of cutaneous tissue (1,15) and point to the possibility that this enzyme might participate in skin repair.…”
Section: Significancesupporting
confidence: 92%
“…1F). These results confirm previous data documenting the presence of FAAH in cellular components of cutaneous tissue (1,15) and point to the possibility that this enzyme might participate in skin repair.…”
Section: Significancesupporting
confidence: 92%
“…Any such approach will need to be precisely tuned to the developmental timeline and to the specific pathogenetic underpinnings of autism in the single patient. Our understanding of eCB signaling in autism is still in its infancy compared with other disorders of the central nervous system or of peripheral tissues, where eCBbased therapies have already reached preclinical and clinical phases [4]. However, research in this field is rapidly evolving, and novel drugs able to hit specifically a distinct element of the eCB system are developed at a surprising speed [4].…”
Section: Discussionmentioning
confidence: 99%
“…Our understanding of eCB signaling in autism is still in its infancy compared with other disorders of the central nervous system or of peripheral tissues, where eCBbased therapies have already reached preclinical and clinical phases [4]. However, research in this field is rapidly evolving, and novel drugs able to hit specifically a distinct element of the eCB system are developed at a surprising speed [4]. Among them, those that target metabolic enzymes of eCBs, and, at the same time, key enzymes of oxidative pathways like cyclooxygenases seem to hold promise as next-generation therapeutics against human disorders with an inflammatory component [140], and therefore they will possibly result in also being beneficial for ASD.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Scientific interest in the pharmacology of cannabis constituents has steadily grown over the last 50 years since the isolation and synthesis of THC and CBD (isolated in 1940, characterized in 1963, and synthesized in the late 1960s) [8][9][10][11]. The action of THC at CB 1 R and the endocannabinoid system [including CB 1 R and CB 2 R, their endogenous ligands (the endocannabinoids), and metabolic enzymes for endocannabinoid biosynthesis and inactivation] were discovered in the late 1980s and early 1990s, and has been the most intensively studied aspect of cannabis pharmacology [12,13]. A PubMed search (May 2015) identified 19, 095 references on 'cannabinoid', 13,919 on 'cannabis', 6740 on 'endocannabinoid', 6579 on THC, and 1351 on CBD.…”
mentioning
confidence: 99%